Glucagon-like Peptide-1/Glucose Dependent Insulin Stimulating Polypeptide Double Receptor Agonist-Tirzepatide

VernacularTitle:胰高血糖素样肽-1/葡萄糖依赖性促胰岛素多肽双受体激动剂替西帕肽
Author: Jing ZHANG ^{1
,

2} ; Yilin HOU ; Chaozi ZHANG ; Guangyao SONG
Author Information

1. 河北医科大学研究生学院内科教研室,石家庄 050017
2. 河北省人民医院内分泌科,石家庄 050051
Keywords: Tirzepatide; Type 2 diabetes mellitus; Glucagon-like Peptide-1 analogs; Glucagon-like peptide-1/glucose dependent insulin stimulating polypeptide double receptor agonist
From: Herald of Medicine 2024;43(4):595-600
CountryChina
Language:Chinese
Abstract: Tirzepatide,a new glucagon-like peptide-1/glucose dependent insulin stimulating polypeptide(GLP-1/GIP)double receptor agonist,has been clinically shown to have a strong hypoglycemic effect and a very significant effect on reducing body mass.It can improve insulin sensitivity,and has superior cardiovascular protection and the effect of improving nonalcoholic fatty liver disease/nonalcoholic steatohepatitis(NAFLD/NASH),with few side effects and good compliance.As a dual gut hor-mone agonist,tirzepatide shows strong potential to improve metabolic levels.This article reviews the mechanism of action and clini-cal studies of the GLP-1/GIP dual receptor agonist tirzepatide.